Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$29.22 USD

29.22
24,234,574

-0.05 (-0.17%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $29.21 -0.01 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 14% (34 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Can Rhopressa's Approval Drive Aerie (AERI) in Q4 Earnings?

Aerie (AERI) looks poised for a beat when it reports Q4 results (due on Feb 28) on the back of lead drug Rhopressa's approval.

    Momenta's (MNTA) Earnings & Revenues Surpass Estimates in Q4

    Momenta (MNTA) delivers better-than-expected fourth-quarter results on the back of an upfront payment from CSL.

      Stock Market News For Feb 20, 2018

      Markets closed mostly higher on Friday.

        Bristol-Myers Squibb (BMY) in Focus: Stock Moves 5.6% Higher

        Bristol-Myers Squibb (BMY) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

          FDA Sets the Stage for Earlier-Stage Alzheimer's Treatments

          FDA's proposed guidelines come in a week when major disappointments in the field were announced by companies developing drugs to treat Alzheimer's.

            Exelixis Reports Positive Data From Thyroid Carcinoma Trial

            Exelixis (EXEl) announces positive data from a phase II trial of cabozantinib for the first-line treatment of metastatic radioiodine-refractory differentiated thyroid carcinoma.

              Merck (MRK) Halts Another Late Stage Study on Alzheimer's

              Merck (MRK) stalls a phase III study evaluating verubecestat for the treatment of prodromal Alzheimer's disease on the recommendation of an external data monitoring committee.

                5 Low Leverage Stocks You Will Love on Valentine's Day

                Since debt-burden companies are risky to invest in, especially at times of market turmoil; risk-averse investors should go for low leverage stocks.

                  Pfizer Announces FDA Acceptance of NDA for NSCLC Candidate

                  Pfizer's (PFE) regulatory applications seeking approval for tyrosine kinase inhibitor, lorlatininb, for treating second or later line NSCLC accepted in the United States, Europe and Japan.

                    FDA Okays J&J's Prostate Cancer Drug in First-Line Setting

                    The FDA lends a nod to the label expansion of Johnson & Johnson's (JNJ) Zytiga in combination with prednisone for metastatic high-risk castration-sensitive prostate cancer.

                      Sweta Killa headshot

                      Solid Q4 Earnings Drive Pharma ETF Outlook

                      Although pharma ETFs saw terrible trading over the past one month in the latest global market rout, the string of earnings beat bolstered confidence in the space.

                        Glaxo's (GSK) Begins Phase III HIV Two-Drug Regimen Study

                        Glaxo's (GSK) ViiV Healthcare commences phase III study on combo regimen of dolutegravir and lamivudine for maintenance of viral suppression in HIV-1 infection patients treated with TAF-based regimen.

                          The Zacks Analyst Blog Highlights: CA, Quest Diagnostics, Pfizer, United Parcel and U.S. Bancorp

                          The Zacks Analyst Blog Highlights: CA, Quest Diagnostics, Pfizer, United Parcel and U.S. Bancorp

                            FDA Approves Gilead (GILD) HIV Triple Therapy, Stock Up

                            Gilead (GILD) gets a huge boost with the FDA's approval of its once-daily single tablet regimen (STR), Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF) for the treatment of HIV-1 infection.

                              Tirthankar Chakraborty headshot

                              Wall Street See-Saws on Spike in Bond Yields: 5 Safest Bets

                              Rise in bond yields increased the opportunity cost of investing in other asset classes such as equities, thus, making them less attractive.

                                Pfizer Files for Xtandi in Early Stage Prostate Cancer

                                Pfizer (PFE) announces detailed results from a late-stage study which can expand the label of Xtandi to include early-stage patients. It also files for approval in U.S. and EU.

                                  Bristol-Myers (BMY) Beats on Q4 Earnings, Eliquis Impresses

                                  Bristol-Myers (BMY) beats estimates on both counts in the fourth quarter. Eliquis records solid sales.

                                    Allergan's Anti-Infective Drug Avycaz Receives Third FDA Nod

                                    The FDA's label expansion approval for Allergan's (AGN) Avycaz marks its third therapeutic indication nod for the anti-infective drug in the United States.

                                      Swarup Gupta headshot

                                      Dow 30 Stock Roundup: BA, MSFT, AAPL, MCD, PFE, V Earnings Impress

                                      The Dow experienced a mixed week, losing momentum over the first few days before rebounding over the next two.

                                        The Zacks Analyst Blog Highlights: Pfizer, PayPal, Raytheon, Aetna and Kinder Morgan

                                        The Zacks Analyst Blog Highlights: Pfizer, PayPal, Raytheon, Aetna and Kinder Morgan

                                          Momenta Up on FDA's Amendment of McPherson Compliance Status

                                          Momenta's (MNTA) stock gains as investors were relieved after the FDA classified the outcome of fourth-quarter 2017 reinspection of Pfizer's McPherson facility as Voluntary Action Indicated.

                                            Q4 Results Remain Positive, Market Dips

                                            Q4 Results Remain Positive, Market Dips

                                              Mark Vickery headshot

                                              Markets Deeper in the Red, Q4 Reports Stay Healthy

                                              Keeping with Q4 earnings results, here are 4 leaders in their respective spaces and how well they have performed relative to expectations.

                                                Pfizer (PFE) Stock Falls Despite Q4 Earnings & Sales Beat

                                                Pfizer (PFE) beats expectations for both earnings and revenues in Q4 and issues an upbeat guidance for 2018. However, shares decline in pre-market trading.

                                                  Pfizer (PFE) Q4 Earnings & Sales Top, 2018 View Upbeat

                                                  Pfizer (PFE) beat expectations for both earnings and revenues in Q4. It issued an upbeat guidance for 2018.